Now that we are on the NASDAQ, what we need now is a "buy" recommendation from some big boy brokerage firm, then we are on our way to becoming more noticeable to prospective investors. Being on OTC, they were not going to be touched by such firms. Articles like recently published in Lancet could make such a thing possible.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.